Roche Holding AG and Carmot Therapeutics Inc. · acquisition

Headline: $3.1 billion (contingent)

Boehringer Ingelheim International GmbH and Zealand Pharma A/S · partnership

Headline: Up to $500 million (contingent)

Eli Lilly and Company and Chugai Pharmaceutical Co., Ltd. · licensing

Headline: Not disclosed (contingent)

Novo Nordisk A/S and Emisphere Technologies Inc. · licensing

Headline: Up to $105 million (contingent)